IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Recurrent Skin Carcinoma
National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
28 Active assets in the Recurrent Skin Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | B |
Binimetinib H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | B |
Larotrectinib National Cancer Institute (NCI) | Phase 2 | CCC |
Tas-102 National Cancer Institute (NCI) | Phase 2 | CCC |
Crizotinib National Cancer Institute (NCI) | Phase 2 | CCC |
View all 34 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →